Bruton’s tyrosine kinase (BTK) is at the core of present day treatment in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) which in turn is redefining first line and relapsed ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and ...

Head-to-Head Study Highlights Rocbrutinib as the World's First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical ...

Imugene has reported promising Phase 1b data for azer-cel, its allogeneic CD19 CAR T-cell therapy, in a CAR T-naïve cohort of patients with relapsed or refractory non-Hodgkin lymphoma and chronic ...

Late-breaking Phase 3 SUCCESSOR-2 study results highlight potential of mezigdomide, a novel CELMoD from the Company’s targeted protein degradation platform, in relapsed or refractory multiple ...

A charity cyclist will be visiting Limekilns as part of her 541km ride in aid of Teenage Cancer Trust. Deborah Reid, 59, is cycling from Aberdeen to Edinburgh to raise funds for the good cause which ...

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has reported encouraging early response rates from the CAR T-naïve cohort of its ...

For the roughly 4,000 to 5,000 Americans diagnosed with mantle cell lymphoma each year, running out of treatment options can happen fast. The cancer is one of the more aggressive forms of non-Hodgkin ...

In part 2 of his recent interview with The American Journal of Managed Care ®, Adam Kittai, MD, addressed how he counsels ...

Propensity-matched TriNetX cohorts of ibrutinib and acalabrutinib recipients showed atrial fibrillation incidence rising with ...